Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | XBP1 | P17861 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10189422 | 1.00 | POLB (0.48) | POLBHSD17B10SIGMAR1KMT2AMEN1 | |
| SCHEMBL21700157 | 1.00 | POLB (0.48) | POLBHSD17B10SIGMAR1KMT2AMEN1 | |
| SCHEMBL621552 | 1.00 | POLB (0.48) | POLBHSD17B10SIGMAR1KMT2AMEN1 | |
| Vaborbactam SCHEMBL18967758 | 0.93 | SIGMAR1 (0.45) | POLBHSD17B10SIGMAR1KMT2AMEN1 | |
| Vaborbactam SCHEMBL22726486 | 0.93 | SIGMAR1 (0.45) | POLBHSD17B10SIGMAR1KMT2AMEN1 | |
| Vaborbactam SCHEMBL620289 | 0.93 | SIGMAR1 (0.45) | POLBHSD17B10SIGMAR1KMT2AMEN1 | |
| Vaborbactam SCHEMBL622398 | 0.93 | SIGMAR1 (0.45) | POLBHSD17B10SIGMAR1KMT2AMEN1 | |
| SCHEMBL10158979 | 0.90 | POLB (0.47) | POLBHSD17B10SIGMAR1KMT2AMEN1 | |
| SCHEMBL10158925 | 0.90 | POLB (0.47) | POLBHSD17B10SIGMAR1KMT2AMEN1 | |
| SCHEMBL20661301 | 0.86 | POLB (0.47) | POLBHSD17B10SIGMAR1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277571-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2023-09-07 | — | — | US | disclosed |
| US-11684629-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | MELINTA SUBSIDIARY CORP. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220125813-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2022-04-28 | — | — | US | disclosed |
| US-11090319-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | MELINTA SUBSIDIARY CORP. (US) | 2021-08-17 | — | — | US | disclosed |
| US-20200222434-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2020-07-16 | — | — | US | disclosed |
| EP-3666778-A1 | A CRYSTALLINE CYCLIC BORONIC ACID ESTER DERIVATIVE, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF | Rempex Pharmaceuticals, Inc. (US) | 2020-06-17 | — | — | EP | disclosed |
| US-10639318-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | REMPEX PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| EP-3412676-B1 | CYCLIC BORONIC ACID ESTER DERIVATIVES, METHOD FOR THE PREPARATION AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20190076449-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2019-03-14 | — | — | US | disclosed |
| US-10183034-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | REMPEX PHARMACEUTICALS, INC. (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180214465-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2018-08-02 | — | — | US | disclosed |
| US-20180207183-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | MELINTA SUBSIDIARY CORP. | 2018-07-26 | — | — | US | disclosed |
| EP-2603514-B1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS INC (US) | 2018-07-18 | — | — | EP | disclosed |
| US-10004758-B2 | Cyclic boronic acid ester derivatives and methods of making the same | REMPEX PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180071325-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHODS OF MAKING THE SAME | MELINTA SUBSIDIARY CORP. | 2018-03-15 | — | — | US | disclosed |
| US-9694025-B2 | Cyclic boronic acid ester derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160220591-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | MELINTA SUBSIDIARY CORP. | 2016-08-04 | — | — | US | disclosed |
| US-9296763-B2 | Cyclic boronic acid ester derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-8680136-B2 | Cyclic boronic acid ester derivatives and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| WO-2012021455-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | REMPEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180207183-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, SLC10A2, ABCB11 | POLB 1208/4885HSD17B10 2309/4885SIGMAR1 2295/4885 |
| US-20180214465-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | POLB 1037/4885HSD17B10 2830/4885SIGMAR1 1722/4885 |
| US-10183034-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | POLB 1037/4885HSD17B10 2830/4885SIGMAR1 1722/4885 |
| US-20160220591-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND THERAPEUTIC USES THEREOF | BCL6B, BCL6, BCL9 | POLB 1247/4885HSD17B10 2952/4885SIGMAR1 2895/4885 |
| US-20180071325-A1 | CYCLIC BORONIC ACID ESTER DERIVATIVES AND METHODS OF MAKING THE SAME | BCL6B, BCL6, BCR | POLB 841/4885HSD17B10 2681/4885SIGMAR1 3001/4885 |
| US-20200222434-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | POLB 1037/4885HSD17B10 2830/4885SIGMAR1 1722/4885 |
| US-10639318-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | POLB 1037/4885HSD17B10 2830/4885SIGMAR1 1722/4885 |
| US-20220125813-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | POLB 1037/4885HSD17B10 2830/4885SIGMAR1 1722/4885 |
| US-20190076449-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | POLB 1037/4885HSD17B10 2830/4885SIGMAR1 1722/4885 |
| US-11090319-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | POLB 1037/4885HSD17B10 2830/4885SIGMAR1 1722/4885 |
| US-11684629-B2 | Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives | BCL6B, BCL6, SLC10A2 | POLB 1037/4885HSD17B10 2830/4885SIGMAR1 1722/4885 |
| US-10004758-B2 | Cyclic boronic acid ester derivatives and methods of making the same | BCL6B, BCL6, BCR | POLB 841/4885HSD17B10 2681/4885SIGMAR1 3001/4885 |
| US-20230277571-A1 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | BCL6B, BCL6, SLC10A2 | POLB 1037/4885HSD17B10 2830/4885SIGMAR1 1722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.